will let you [400:10%: Central nervous system: Foreign body sensation of eye (14% to 15%) Ophthalmic: Corneal opacity (haze) (64% to 71%), corneal disease (3% to 28%), eye pain (17% to 26%), punctate keratitis (20% to 25%), corneal edema (in progressive keratoconus patients: 24%; all other patients: 3% to 9%), photophobia (2% to 19%), blurred vision (16% to 17%), ocular hyperemia (8% to 14%), dry eye syndrome (6% to 14%), decreased visual acuity (10% to 11%) 1% to 10%: Central nervous system: Headache (4% to 8%) Ophthalmic: Increased lacrimation (5% to 10%), eye discomfort (9%), conjunctival edema (7%), eyelid edema (5% to 6%), anterior chamber inflammation (2% to 6%), visual impairment (3% to 4%), blepharitis (3%), keratitis (1% to 3%), asthenopia (2%), diplopia (2%), eye discharge (2%), eye pruritus (2%), vitreous detachment (2%), eye injury (associated with device; 1% to 2%), visual halos around lights (1% to 2%) Warnings/Precautions Concerns related to adverse effects: Ulcerative keratitis: May occur; monitor for resolution of epithelial defects. Monitoring Parameters Resolution of epithelial defects Pregnancy Considerations Animal reproduction studies have not been conducted with riboflavin 5'-phosphate. The manufacturer recommends that the corneal collagen cross-linking procedure not be done during pregnancy. Pregnancy may be a risk factor for the progression of keratoconus (Bilgihan 2011). Patient Education Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?) Patient may experience blurred vision, seeing floaters, dry eyes, foreign body sensation, tearing, headache, or sensitivity to light. Have patient report immediately to prescriber vision changes, severe eye pain, or severe eye irritation (HCAHPS). Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions. Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients. Print this page] Recently Approved Lonhala Magnair Lonhala Magnair (glycopyrrolate) is a long-acting muscarinic antagonist (LAMA) bronchodilator for... Ozempic Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) analog administered once-weekly for the... Ogivri Ogivri (trastuzumab-dkst) is a HER2 / neu receptor antagonist biosimilar to Herceptin indicated for... Sublocade Sublocade (buprenorphine) is a once-monthly injectable partial opioid agonist formulation for the... More organisation
one-way links Riboflavin 5'-Phosphate charges
EmoticonEmoticon